Botulinum Neurotoxin Type B (BoNT/B) antibody

Details for Product No. ABIN179725
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Clostridium botulinum (C. botulinum)
Mouse (Murine)
(3), (2)
Clonality (Clone)
Monoclonal ()
Flow Cytometry (FACS), Cell-ELISA (cELISA)
(3), (2), (1), (1), (1)
Pubmed 4 references available
Quantity 100 μg
Shipping to United States (Change)
Availability Will be delivered in 5 to 6 Business Days
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Catalog No. ABIN179725
375.10 $
Plus shipping costs $45.00

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen genetic immunisation with cDNA encoding BoNT/B
Clone GR-3G7
Isotype IgG1
Specificity Anti-BoNT/B
Purification Protein G
Alternative Name BoNT B, Lightchain
Background Botulinum neurotoxin type B (BoNT/B) is produced by Clostridium botulinum, a genetically diverse class of anaerobic, spore-forming, gram-positive bacilli. Seven different botulinum toxin groups have been identified serologically and are called botulinum toxin type A,B,C,D,E,F, and G. BoNT/B is a two-chain polypeptide with a 100-kDa heavy chain, which is responsible for neurospecific binding joined by a disulphide bond to a 50-kDa light chain, a zinc-endopeptidase which blocks neurotransmitter release. BoNT/B is one of the most poisonous naturally occurring substances. It inhibits acetylcholine release from neuromuscular junctions while it is used as an important therapeutic mainstay in the treatment of spasticity disorders and as a cosmetic treatment.
Application Notes Flow cytometry: 1.2 µg/10^6 cells
CELISA: 1:200 - 1:400
For each application a titration should be performed to determine the optimal concentration.
Restrictions For Research Use only
Concentration 2 mg/mL
Buffer PBS, pH 7.2
Handling Advice Avoid repeated freezing and thawing.
Storage 4 °C
Storage Comment short term: 2 °C - 8 °C, long term: -20 °C
Supplier Images
anti-Botulinum Neurotoxin Type B (BoNT/B) antibody FACS analysis of BOSC23 cells using GR-3G7. BOSC23 cells were transiently trans-fected with an expression vector encoding eitherBoNT/B(red curve) or an irrelevant protein (controltransfectant). Binding of GR-3G7 was detected with a PE conjugated secondary antibody. A positive signal was obtained only with BoNT/B transfected cells.
anti-Botulinum Neurotoxin Type B (BoNT/B) antibody (2) BOSC23 cells were transiently transfected withexpression vectors containing the cDNA of the lightchain of botulinum toxin A-F. Expression of the constructs was tested with an anti-myc antibody (greencurves). An irrelevant monoclonal antibody served as an
anti-Botulinum Neurotoxin Type B (BoNT/B) antibody (3) SDS-PAGE analysis of purified GR-3G7 monoclonal antibody. Lane 1: molecular weight marker, Lane 2: 2 ug ofpurified GR-3G7 antibody. Proteins were separated by SDS-PAGE and stained with RAPID Stain Reagent.
General Papapetropoulos, Singer: "Botulinum toxin in movement disorders." in: Seminars in neurology, Vol. 27, Issue 2, pp. 183-94, 2007 (PubMed).

Tonello, Morante, Rossetto et al.: "Tetanus and botulism neurotoxins: a novel group of zinc-endopeptidases." in: Advances in experimental medicine and biology, Vol. 389, pp. 251-60, 1997 (PubMed).

DasGupta: "Structure and biological activity of botulinum neurotoxin." in: Journal de physiologie, Vol. 84, Issue 3, pp. 220-8, 1991 (PubMed).

Schiavo, Benfenati, Poulain et al.: "Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin." in: Nature, Vol. 359, Issue 6398, pp. 832-5, 1992 (PubMed).

Validation Images
Did you look for something else?
back to top